Article
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
Alimentary pharmacology & therapeutics - 1 Oct 2015
Zeuzem S, Flisiak R, Vierling J M, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu S-J, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel L H, Brass C, Naoumov N V
Abstract excerpt
BACKGROUND: Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. AIM: To evaluate efficacy and safety of ALV plus peginterferon-α2a and ribavirin (PR) in treatment-naïve patients with chronic HCV genotype 1 infection. METHODS: Double-blind, randomised, placebo-controlled, Phase 3 study evaluating ALV 600 mg once daily...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.